Katya Uzunova, Andrey Petrov, Emil Gatchev, Velichka Pavlova, Elena Filipova*, Cintia Jimenez, Krassimir Kalinov and Toni Vekov
Background and objective: The combination antihypertensive therapy has shown greater blood pressure lowering potential as well as better adherence to the treatment. Therefore, a new generic fixed-dose combination containing irbesartan and hydrochlorothiazide was developed and rate and extend of absorption were compared with reference formulation to prove its bioequivalence in healthy volunteers.
Methods: A single-centre, open-label, randomized, two-period, crossover, single dose study under fasting conditions, including at least 7-days washout period, was performed in 30 healthy male and female volunteers. Twenty blood samples were collected in each study period: prior to dosing (0:00) and up to 72:00 hours after dosing and plasma concentrations of irbesartan and hydrochlorothiazide were analysed using preliminary validated methods.
Results: The 90% CIs for the geometric mean ratios of test and reference of Cmax and AUC0–t were 89.22% to 98.80% and 100.58% to 115.11%, respectively, for irbesartan and 91.80% to 122.96% and 94.88% to 117.56%, respectively. Thus, the corresponding ratios of Cmax and AUC0-t for irbesartan and hydrochlorothiazide met the predetermined criteria for bioequivalence (90% confidence intervals of the geometric mean ratios of test and reference within the 80.00% - 125.00%). Both the test and reference products demonstrated good tolerability profile in this population, and no serious AEs were observed.
Conclusions: Therefore, the test product (Irbesartan/hydrochlorothiazide 300/25 mg film-coated tablets, manufactured by Tchaikapharma High Quality Medicines Inc., Bulgaria) and the reference product (CoAprovel 300/25 mg film-coated tablets, manufactured by Sanofi Clir SNC, France) are considered bioequivalent.
Published Date: 2022-04-25; Received Date: 2022-03-30
